Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality. - Wikidata - awgldk - TriplyDB

Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality.

Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality.

http://www.wikidata.org/entity/Q37398972

about

Statin, testosterone and phosphodiesterase 5-inhibitor treatments and age related mortality in diabetes Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure.

P2860

Q37697561-A0967928-81F2-4091-B8BF-79A3D27CA9AE Q39141728-B0C957C6-4683-4EAD-A4D7-FF29B655B7B5

P2860

Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality.

http://www.wikidata.org/entity/Q37398972

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 26 July 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Phosphodiesterase type-5 inhib ...... uction in all-cause mortality.

@en

Phosphodiesterase type-5 inhib ...... uction in all-cause mortality.

@nl

type

label

Phosphodiesterase type-5 inhib ...... uction in all-cause mortality.

@en

Phosphodiesterase type-5 inhib ...... uction in all-cause mortality.

@nl

prefLabel

Phosphodiesterase type-5 inhib ...... uction in all-cause mortality.

@en

Phosphodiesterase type-5 inhib ...... uction in all-cause mortality.

@nl

P1433

Q37398972-1F3F09E1-2CBA-46ED-8799-DCFBBD0E7497

P1476

Q37398972-2A38B86B-1EF4-4442-88E8-60B405891F64

P2093

Q37398972-0FD1A2B0-DFC6-4451-A2AC-E6F7B41FAD3A

Q37398972-1D76B5F2-34C7-4C00-BF6F-BA4FE1A3F7A4

Q37398972-574E940A-93B2-470E-924F-C7978287CAAC

Q37398972-A25D20C7-FE79-4666-B417-37040FAFA37B

Q37398972-C20854F1-70DC-48FA-B48D-13656A3F55FB

Q37398972-D15EA34F-D2E3-4B96-8D82-C0448C048779

P2860

Q37398972-0A1FC35F-19B2-4396-9796-DB8B1F5EBA0A

Q37398972-0DC99B82-3D8C-48BC-B292-392C38FCD07F

Q37398972-15AB74D3-2734-475D-873A-CACEBC333BDB

Q37398972-22B1C3C7-53C7-4439-8D17-1F1DD962FE9C

Q37398972-27BC0CF8-BFBF-4C29-8FEB-6AE37B3E3302

Q37398972-3D648D0D-0806-4B88-B911-55B0AE825809

Q37398972-432EF5F2-3B35-47A4-8A7E-4574C469D776

Q37398972-4751AC59-1405-4F29-9A7A-1F023BFE6743

Q37398972-4768E6E9-5E46-4FA3-8416-7EF7BE87D69A

Q37398972-4A5D1C33-E54C-41A0-84AB-66EEEB68A115

P304

Q37398972-ED2C9428-33E6-4DBD-AAAC-923933460A34

P31

Q37398972-3E556B66-87AA-4202-B861-CA480A7AA1EF

P356

Q37398972-27CBE9AF-EA7A-43A1-BCDB-5151D1B26EF8

P407

Q37398972-91101008-9A6B-473A-A474-1E2F3D5DF4C5

P433

Q37398972-0D2F1144-3A0D-459A-B8D1-A090BA9CD249

P478

Q37398972-C772A2C1-12BA-4CDB-8B8B-BF839ABD6783

P50

Q37398972-0D8D2A68-9589-4EB6-813D-11CC612DD81E

Q37398972-786EEBAB-FB05-46D0-8001-956F22518CD3

Q37398972-F1327CC1-A77F-4F7A-87C8-3AACAD8A8CFF

P577

Q37398972-F383A02E-7CB5-4735-9ACB-ED635E323FDA

P698

Q37398972-867EBCA5-79EF-4071-BD76-83DCEDE420CA

P921

Q37398972-9701B6C9-27BB-4867-99BA-A245EC4DC232

P932

Q37398972-5CC013B5-2FCB-4A03-AB41-CB82FDA3E694

P356

HEARTJNL-2015-309223

P1433

P1476

Phosphodiesterase type-5 inhib ...... duction in all-cause mortality

@en

P2093

Adrian H Heald

http://www.w3.org/2001/XMLSchema#string

Andrew W Trafford

http://www.w3.org/2001/XMLSchema#string

Geoff Hackett

http://www.w3.org/2001/XMLSchema#string

Kazem Rahimi

http://www.w3.org/2001/XMLSchema#string

Mark Woodward

http://www.w3.org/2001/XMLSchema#string

Mike Kirby

http://www.w3.org/2001/XMLSchema#string

P2860

Sex and death: are they related? Findings from the Caerphilly Cohort Study

Prediction of cardiovascular events and all-cause mortality with erectile dysfunction: a systematic review and meta-analysis of cohort studies

Phosphodiesterases and cardiac cGMP: evolving roles and controversies

Cardiovascular disease in type 2 diabetes: challenge for treatment and prevention

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database.

Diabetes, obesity and erectile dysfunction: field overview and research priorities.

Phospholemman Ser69 phosphorylation contributes to sildenafil-induced cardioprotection against reperfusion injury.

Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials.

Sildenafil and vardenafil but not nitroglycerin limit myocardial infarction through opening of mitochondrial K(ATP) channels when administered at reperfusion following ischemia in rabbits

P304

1750-1756

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/HEARTJNL-2015-309223

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

102

http://www.w3.org/2001/XMLSchema#string

P50

David Charles Hutchings

P577

2016-07-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27465053

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

5099221

http://www.w3.org/2001/XMLSchema#string